NEUROONE MEDICAL TECHNOLOGIES Corp

For the period ended Sep 30, 2024. Filed Dec 17, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Dec 17, 2024

NMTC$0.89+0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

	As of September 30,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$1,460,042	$5,322,493
Accounts receivable	176,636	—
Inventory	2,635,153	1,726,686
Deferred offering costs	142,633	—
Prepaid expenses	216,461	263,746
Total current assets	4,630,925	7,312,925
Intangible assets, net	67,262	89,577
Right-of-use asset	254,910	169,059
Property and equipment, net	416,843	525,753
Total assets	$5,369,940	$8,097,314
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$1,029,206	$685,104
Accrued expenses and other liabilities	1,184,014	1,107,522
Total current liabilities	2,213,220	1,792,626
Warrant liability	2,140,315	—
Operating lease liability, long term	194,392	55,284
Total liabilities	4,547,927	1,847,910
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding.	—	—
Common stock, $0.001 par value; 100,000,000 shares authorized; 30,816,499 and 23,928,945 shares issued and outstanding as of September 30, 2024 and 2023, respectively.	30,816	23,929
Additional paid–in capital	75,795,610	68,911,778
Accumulated deficit	(75,004,413)	(62,686,303)
Total stockholders’ equity	822,013	6,249,404
Total liabilities and stockholders’ equity	$5,369,940	$8,097,314

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.